tirzepatide Zepbound
Selected indexed studies
- Tirzepatide for Obesity Treatment and Diabetes Prevention. (N Engl J Med, 2025) [PMID:39536238]
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. (Lancet, 2023) [PMID:37385275]
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. (N Engl J Med, 2024) [PMID:38912654]
_Worker-drafted node — pending editorial review._
Connections
tirzepatide Zepbound is a side effect of
Sources
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. (2024) pubmed
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. (2024) pubmed
- Tirzepatide for Obesity Treatment and Diabetes Prevention. (2025) pubmed
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. (2023) pubmed
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. (2024) pubmed
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. (2022) pubmed
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. (2025) pubmed
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. (2024) pubmed
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. (2024) pubmed
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. (2021) pubmed